Precision AQ
Alex GrosvenorSenior Vice President & Managing Director
Alex Grosvenor leads the International Pricing & Market Access Strategy practice, which he established in 2015. Alex brings over 20 years’ consulting experience in the biopharmaceutical industry. He specializes in complex pricing strategies, including cross-indication strategy, launch sequencing and international price referencing. He has worked across multiple therapy areas, including oncology, immunology, cardiovascular, orphan indications and cell & gene therapies. Prior to joining Precision, Alex was a Senior Director in the Pricing & Market Access practice for ICON plc (formerly PriceSpective). And before ICON, Alex was a Project Director at Apex Healthcare Consulting, a consultancy providing commercial and strategic evaluations for biopharmaceutical companies in specialty markets. Alex also worked at Wood Mackenzie, an Edinburgh-based advisory firm to the life sciences industry and started his career as a journalist at the Financial Times. Alex holds a BSc (Hons) degree in Biochemistry from the University of St Andrews.
Insights from Alex Grosvenor
Commercialization & Access | White Paper
China Market Access After NRDL Maturity: What Comes After the Price Reset?
NRDL inclusion is no longer the finish line. See why reimbursement alone doesn’t guarantee real-world utilization.